Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 35
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Metabolomic signatures predict seven-year mortality in clinically stable COPD patients

  • Enríquez Rodríguez, César Jessé
  • Agranovich, Bella
  • Pascual Guàrdia, Sergi, 1979-
  • Faner, Rosa
  • Camps-Ubach, Ramon
  • Castro-Acosta, Ady Angélica
  • Lopez-Campos, Jose Luis
  • Peces-Barba Romero, Germán
  • Seijó Maceiras, Luis
  • Caguana Vélez, Oswaldo Antonio
  • Rodríguez Chiaradia, Diego Agustín
  • Barreiro Portela, Esther
  • Monsó Molas, Eduard
  • Cosío, Borja G.
  • Abramovich, Ifat
  • Agustí García-Navarro, Àlvar
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
  • Biomepoc Group
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with high mortality. Early identification of patients at increased risk of death remains a major clinical challenge. This pilot study aimed to explore whether plasma metabolomic profiling could aid in the prediction of long-term (7-year) mortality and provide insight into potential underlying mechanisms. Plasma samples from 54 randomly selected stable COPD patients were analyzed using both untargeted and semi-targeted LC-MS approaches. After excluding patients with unclear death data, non-COPD-related deaths and metabolomic outliers, 41 individuals were included in the final analysis. During follow-up, 13 patients (32%) died, and 28 survived. Univariate analysis identified 12 metabolites 'mainly amino acids' that differed significantly between the two groups. Functional analysis suggested a significant disruption in energy production pathways. Predictive models developed using machine learning algorithms, consisting of either ten metabolites alone or nine metabolites plus FEV, achieved high accuracy for 7-year mortality prediction, with the latter model performing slightly better. Internal validation was conducted using five-fold cross-validation. While exploratory, these findings support the hypothesis that early metabolic alterations, particularly in energy pathways, may contribute to long-term mortality risk in stable COPD patients, and could complement traditional prognostic markers such as FEV., This study was supported by joint funding from the Spanish Ministry of Economy and Competitiveness and the European Union (project SAF2014-54371); the Instituto de Salud Carlos III (ISCIII) and the European Union (projects PI21/00785 and M-BAE BA22/00009); SEPAR Grants (2016, and 2019); a SOCAP Grant (2020); and an unrestricted grant from Menarini Spain (2015-2019). César Jessé Enríquez-Rodríguez holds a predoctoral fellowship (PFIS, ref. FI22/00003) and a Research Personnel Mobility Grant (M-AES MV23/00012), both awarded by ISCIII and co-funded by the European Union.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Relationship between respiratory microbiome and systemic inflammatory markers in COPD: A pilot study

  • Casadevall Fusté, Carme
  • Quero, Sara
  • Millares, Laura
  • Faner, Rosa
  • Cosío, Borja G.
  • Peces-Barba Romero, Germán
  • Castro-Acosta, Ady Angélica
  • Montón, Concepción
  • Palou, Alexandre
  • Pascual Guàrdia, Sergi, 1979-
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • Monsó Molas, Eduard
  • BIOMEPOC group
The respiratory microbiome may influence the development and progression of COPD by modulating local immune and inflammatory events. We aimed to investigate whether relative changes in respiratory bacterial abundance are also associated with systemic inflammation, and explore their relationship with the main clinical COPD phenotypes. Multiplex analysis of inflammatory markers and transcript eosinophil-related markers were analyzed on peripheral blood in a cohort of stable COPD patients (n = 72). Respiratory microbiome composition was analyzed by 16S rRNA microbial sequencing on spontaneous sputum. Spearman correlations were applied to test the relationship between the microbiome composition and systemic inflammation. The concentration of the plasma IL-8 showed an inverted correlation with the relative abundance of 17 bacterial genera in the whole COPD cohort. COPD patients categorized as eosinophilic showed positive relationships with blood eosinophil markers and inversely correlated with the degree of airway obstruction and the number of exacerbations during the previous year. COPD patients categorized as frequent exacerbators were enriched with the bacterial genera Pseudomonas which, in turn, was positively associated with the severity of airflow limitation and the prior year's exacerbation history. The associative relationships of the sputum microbiome with the severity of the disease emphasize the relevance of the interaction between the respiratory microbiota and systemic inflammation., This research was funded by Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), ref. CB06/06/0043 and CB06/06/1097; Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, co-funded by the European Union, grant number PI18/00934 and PI21/00785; Spanish Ministry of Economy and Competitivity, co-funded by the European Union, grant number SAF2014-54371; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) ref: 2017SGR442 and 2021SGR-00100; Sociedad Española de Neumología y Cirugía Torácica (SEPAR), grant number 2015 and 2019; Societat Catalana de Pneumologia (SOCAP) grant number 2020 Research Grant. The funders had no role in the design, data collection, data analysis, and reporting of this study.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A pilot study on proteomic predictors of mortality in stable COPD

  • Enríquez Rodríguez, César Jessé
  • Casadevall Fusté, Carme
  • Faner, Rosa
  • Pascual Guàrdia, Sergi, 1979-
  • Castro-Acosta, Ady Angélica
  • López Campos, José Luis
  • Peces-Barba Romero, Germán
  • Seijo, Luis
  • Caguana Vélez, Oswaldo Antonio
  • Monsó Molas, Eduard
  • Rodríguez Chiaradia, Diego Agustín
  • Barreiro Portela, Esther
  • Cosío, Borja G.
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • BIOMEPOC group
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of global mortality. Despite clinical predictors (age, severity, comorbidities, etc.) being established, proteomics offers comprehensive biological profiling to obtain deeper insights into COPD pathophysiology and survival prognoses. This pilot study aimed to identify proteomic footprints that could be potentially useful in predicting mortality in stable COPD patients. Plasma samples from 40 patients were subjected to both blind (liquid chromatography-mass spectrometry) and hypothesis-driven (multiplex immunoassays) proteomic analyses supported by artificial intelligence (AI) before a 4-year clinical follow-up. Among the 34 patients whose survival status was confirmed (mean age 69 ± 9 years, 29.5% women, FEV1 42 ± 15.3% ref.), 32% were dead in the fourth year. The analysis identified 363 proteins/peptides, with 31 showing significant differences between the survivors and non-survivors. These proteins predominantly belonged to different aspects of the immune response (12 proteins), hemostasis (9), and proinflammatory cytokines (5). The predictive modeling achieved excellent accuracy for mortality (90%) but a weaker performance for days of survival (Q2 0.18), improving mildly with AI-mediated blind selection of proteins (accuracy of 95%, Q2 of 0.52). Further stratification by protein groups highlighted the predictive value for mortality of either hemostasis or pro-inflammatory markers alone (accuracies of 95 and 89%, respectively). Therefore, stable COPD patients' proteomic footprints can effectively forecast 4-year mortality, emphasizing the role of inflammatory, immune, and cardiovascular events. Future applications may enhance the prognostic precision and guide preventive interventions., This research was co-funded by the Spanish Ministerio de Economía y Competitividad and the European Union (project SAF2014-54371); the Instituto de Salud Carlos III (ISCIII) and European Union (projects PI21/00785 and M-BAE BA22/00009); SEPAR Grants (2015, 2016 and 2019); an FUCAP Grant (2014); an SOCAP Grant (2020); and Menarini Spain (unrestricted Grant 2015-19). César J. Enríquez-Rodríguez is a recipient of a Predoctoral Grant PFIS (ref. FI22/00003) and a Mobility of Research Personnel Grant (M-AES MV23/00012) from ISCIII and co-funded by the European Union.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

  • Enríquez Rodríguez, César Jessé
  • Casadevall Fusté, Carme
  • Faner, Rosa
  • Castro Costa, Ady
  • Pascual Guàrdia, Sergi, 1979-
  • Seijó Maceiras, Luis
  • López Campos, José Luis
  • Peces-Barba Romero, Germán
  • Monsó Molas, Eduard
  • Barreiro Portela, Esther
  • Cosío, Borja G.
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • BIOMEPOC group
Data de publicació electrònica: 25-03-2024, Background: Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE). The objective of the present study was to contrast the systemic proteomic profile in FE versus NFE. As a reference, we also determined the systemic proteomic profile of healthy controls (HC) and COPD patients during an actual episode of exacerbation (AE). Methods: In the analysis we included 40 clinically stable COPD patients (20 FE and 20 NFE), and 20 HC and 10 AE patients. Their plasma samples were analysed by combining two complementary proteomic approaches: label-free liquid chromatography-tandem mass spectrometry and multiplex immunoassays. Gene Ontology annotation, pathway enrichment and network analyses were used to investigate molecular pathways associated with differentially abundant proteins/peptides (DAPs). Results: Compared with HC, we identified 40 DAPs in FE, 10 in NFE and 63 in AE. Also compared to HC, pathway functional and protein-protein network analyses revealed dysregulation of inflammatory responses involving innate and antibody-mediated immunity in COPD, particularly in the FE group, as well as during an AE episode. Besides, we only identified alterations in the complement and coagulation cascades in AE. Conclusion: There are specific plasma proteome profiles associated with FE, which are partially shared with findings observed during AE, albeit others are uniquely present during the actual episode of AE., Support statement: Funded by project SAF2014-54371 from the Spanish Ministerio de Economía y Competitividad and co-funded by the European Union, project PI21/00785 from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, SEPAR 2015, 2016 and 2019, FUCAP 2014, SOCAP 2020, and Menarini (unrestricted Grant 2015-19). C.J. Enríquez-Rodríguez is a recipient of a Predoctoral Grant PFIS from ISCIII and co-funded by the European Union (ref. FI22/00003). Funding information for this article has been deposited with the Crossref Funder Registry.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

PARP-1 and PARP-2 activity in cancer-induced cachexia: potential therapeutic implications

  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
Skeletal muscle dysfunction and mass loss is a characteristic feature in patients with chronic diseases including cancer and acute conditions such as critical illness. Maintenance of an adequate muscle mass is crucial for the patients' prognosis irrespective of the underlying condition. Moreover, aging-related sarcopenia may further aggravate the muscle wasting process associated with chronic diseases and cancer. Poly(adenosine diphosphate-ribose) polymerase (PARP) activation has been demonstrated to contribute to the pathophysiology of muscle mass loss and dysfunction in animal models of cancer-induced cachexia. Genetic inhibition of PARP activity attenuated the deleterious effects seen on depleted muscles in mouse models of oncologic cachexia. In the present minireview the mechanisms whereby PARP activity inhibition may improve muscle mass and performance in models of cancer-induced cachexia are discussed. Specifically, the beneficial effects of inhibition of PARP activity on attenuation of increased oxidative stress, protein catabolism, poor muscle anabolism and mitochondrial content and epigenetic modulation of muscle phenotype are reviewed in this article. Finally, the potential therapeutic strategies of pharmacological PARP activity inhibition for the treatment of cancer-induced cachexia are also being described in this review., CIBERES, FIS 14/00713 (PEDER), SAF-2014-54371-R, SEPAR 2016, and FUCAP 2016 (Spain) have contributed to support part of the research described in this review.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients

  • Millares, Laura
  • Pascual Guàrdia, Sergi, 1979-
  • Montón, Concepción
  • García-Nuñez, Marian
  • Lalmolda, Cristina
  • Faner, Rosa
  • Casadevall Fusté, Carme
  • Setó, Laia
  • Capilla, Silvia
  • Moreno, Amàlia
  • Castro-Acosta, Ady Angélica
  • Alvarez-Martinez, Carlos José
  • Sibila, Oriol
  • Peces-Barba Romero, Germán
  • Cosio, Borja G.
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • Monsó Molas, Eduard
Background: The respiratory microbiome is altered in COPD patients but its relationship with core components of the disease, such as the severity of airflow limitation, the frequency of exacerbations or the circulating levels of eosinophils, is unclear. Methods: Cross-sectional study comprising 72 clinically stable COPD patients (mean age 68 [SD 7.9] years; FEV1 48.7 [SD 20.1]% of reference) who provided spontaneous sputum samples for 16S rRNA gene amplification and sequencing. The microbiome composition was analysed with QIIME. Results: We observed that: (1) more severe airflow limitation was associated with reduced relative abundance (RA) of Treponema and an increase in Pseudomonas; (2) patients with ≥2 exacerbations the previous year showed a significantly different bacterial community with respect to non-exacerbators (p = 0.014), with changes in 13 genera, including an increase of Pseudomonas, and finally, (3) peripheral eosinophils levels ≥2% were associated with more diverse microbiome [Chao1 224.51 (74.88) vs 277.39 (78.92) p = 0.006; Shannon 3.94 (1.05) vs 4.54 (1.06) p = 0.020], and a significant increase in the RAs of 20 genera. Conclusion: The respiratory microbiome in clinically stable COPD patients varies significantly according to the severity of airflow limitation, previous history of exacerbations and circulating eosinophils levels., This study was funded by FIS PI15/00167 and PI15/02042 from Instituto de Salud Carlos III (ISCIII), SAF 2014–54371 (FEDER) from Ministerio de Economía y Competitividad, Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Laboratorios Menarini S. A, Fundació Pla Armengol and Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). CIBERES is an initiative of the ISCIII.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Bispectral index in hypercapnic encephalopathy associated with COPD exacerbation: a pilot study

  • Chalela Rengifo, Roberto José, 1985-
  • Gallart Gallego, Lluís
  • Pascual Guàrdia, Sergi, 1979-
  • Sancho Muñoz, Antonio
  • Gea Guiral, Joaquim
  • Orozco Levi, Mauricio
Background: Hypercapnic encephalopathy is relatively frequent in severe exacerbations of COPD (ECOPDs), with its intensity usually being evaluated through clinical scales. Bispectral index (BIS) is a relatively new technique, based on the analysis of the electroencephalographic signal, which provides a good approximation to the level of consciousness, having already been validated in anesthesia. Objective: The objective of the study was to evaluate the utility of BIS in the assessment of the intensity of hypercapnic encephalopathy in ECOPD patients. Patients and methods: A total of ten ECOPD patients were included, and the level of brain activity was assessed using BIS and different scales: Glasgow Coma Scale, Ramsay Sedation Scale (RSS), and Richmond Agitation–Sedation Scale. The evaluation was performed both in the acute phase and 3 months after discharge. Results: BIS was recorded for a total of about 600 minutes. During ECOPD, BIS values ranged from 58.8 (95% CI: 48.6–69) for RSS score of 4 to 92.2 (95% CI: 90.1–94.3) for RSS score of 2. A significant correlation was observed between values obtained with BIS and those from the three scales, although the best fit was for RSS, followed by Glasgow and Richmond (r=-0.757, r=0.701, and r=0.615, respectively; P<0.001 for all). In the stable phase after discharge, BIS showed values considered as normal for a wake state (94.6; 95% CI: 91.7–97.9). Conclusion: BIS may be useful for the objective early detection and automatic monitoring of the intensity of hypercapnic encephalopathy in ECOPD, facilitating the early detection and follow-up of this condition, which may avoid management problems in these patients., We are thankful to Jonathan McFarland for his editing aid and to Mireia Admetllo and Camino Fernández for their help in collecting clinical data. This project was funded in part by SAF SAF2014-54371, CIBERES, BRN-Pla Armengol 2014, 2014SGR424, SEPAR 2015, and SEPAR Becario 2015.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients

  • Pascual Guàrdia, Sergi, 1979-
  • Ataya Fernández, Michelle, 1993-
  • Ramírez Martínez, Isabel
  • Yélamos López, José
  • Chalela Rengifo, Roberto José, 1985-
  • Bellido, Salomé
  • López-Botet, M. (Miguel)
  • Gea Guiral, Joaquim
Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive disorder with a heterogeneous presentation and frequent systemic manifestations. Several aspects like persistence in smoking habit, continuous exacerbations, alpha-1-antitrypsin deficiency and inflammatory-immune response, are involved in the pathophysiology and progression of the disease. However, the role of natural killer (NK) cells remains controversial. Otherwise, human cytomegalovirus (HCMV) infection has been reported to induce an adaptive differentiation and expansion of an NK cell subset which carries the CD94/NKG2C receptor, which may contribute to an upset immune defense. For these reasons, our objective is to assess the distribution of NK cells and their subset in COPD patients and some of its phenotypes. Methods: Peripheral blood samples were obtained from 66 COPD patients. HCMV serology and the proportions of total NK cells and the NKG2C+ and NKG2A+ subsets were evaluated by flow cytometry. The NKG2C genotype was also assessed. Results: Eighty-eight per cent of COPD patients were HCMV(+), and the proportions of total NK cells were higher in patients with severe-very severe airway obstruction than in those with only mild-moderate involvement. There were no differences in the proportions of NKG2C+ cells between controls and COPD, either among COPD patients classified by severity of the disease. However, the percentage of NKG2C+ cells were higher in COPD patients with frequent exacerbations than in occasional exacerbators, and higher in cases with reduced lean mass (Fat free mass index) than in those with normal nutritional status. Conclusion: These results suggest a relationship between levels of NKG2C+ cells in COPD patients and clinical variables closely linked to a poor/worse prognosis., SEPAR 2015, MINECO Plan Estatal I + D Retos (SAF2013–49063-C2–1-R, SAF2016–80363-C2–1-R y SAF2014–54371) (FEDER Funds), FUCAP & Menarini.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures

  • Pascual Guàrdia, Sergi, 1979-
  • Badenes Bonet, Diana, 1987-
  • Martín-Ontiyuelo, Clara
  • Zuccarino, Flavio
  • Marín Corral, Judith
  • Rodríguez, Alejandro
  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
BACKGROUND: Vertebral compression fractures (VCF) are common in COPD patients, with osteoporosis being the main cause. The clinical impact of VCF derives mostly from both pain and chest deformity, which may lead to ventilatory and physical activity limitations. Surprisingly, the consequences of VCF on the quality outcomes of hospital care are poorly known. OBJECTIVE: To assess these indicators in patients hospitalized due to a COPD exacerbation (ECOPD) who also have VCF. METHODS: Clinical characteristics and quality care indicators were assessed in two one-year periods, one retrospective (exploratory) and one prospective (validation), in all consecutive patients hospitalized for ECOPD. Diagnosis of VCF was based on the reduction of >20% height of the vertebral body evaluated in standard lateral chest X-ray (three independent observers). RESULTS: From the 248 patients admitted during the exploratory phase, a third had at least one VCF. Underdiagnosis rate was 97.6%, and patients with VCF had more admissions (normalized for survival), longer hospital stays, and higher mortality than patients without (4 [25th-75th percentiles, 2-8] vs 3 [1-6] admissions, P<0.01; 12 [6-30] vs 9 [6-18] days, P<0.05; and 50 vs 32.1% deaths, P<0.01, respectively). The risk of dying in the two following years was also higher in VCF patients (odds ratio: 2.11 [1.2-3.6], P<0.01). The validation cohort consisted of 250 patients who showed very similar results. The logistic regression analysis indicated that both VCF and age were factors independently associated with mortality. CONCLUSION: Although VCF is frequently underdiagnosed in patients hospitalized for ECOPD, it is strongly associated with a worse prognosis and quality care outcomes., This study has been partially funded by SEPAR (264/2012), CIBERES, FIS (12/02534), Plan Nacional I+D+i (SAF-2014 – 54371), Generalitat de Catalunya (2009-SGR-393), and FUCAP (2012).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia

  • Barreiro Portela, Esther
  • Puig Vilanova, Ester, 1987-
  • Salazar Degracia, Anna
  • Pascual Guàrdia, Sergi, 1979-
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
Peripheral muscle weakness and mass loss are characteristic features in severe chronic obstructive pulmonary disease (COPD). We hypothesized that the phosphodiesterase (PDE)-4 inhibitor roflumilast-induced cAMP may ameliorate proteolysis and metabolism in skeletal muscles of COPD patients with severe muscle wasting. In myogenic precursor cells (isolated from muscle biopsies and cultured up to obtain differentiated myotubes) from 10 severe COPD patients and 10 healthy controls, which were treated with 1 μM roflumilast N-oxide (RNO) for three time cohorts (1, 6, and 24 h), genes of antioxidant defense and oxidative stress marker, myogenesis and muscle metabolism, proteolysis (tyrosine release assay) and ubiquitin-proteasome system markers, autophagy, and myosin isoforms were analyzed using RT-PCR and immunoblotting. In COPD patients at 6 h RNO treatment, myotube tyrosine release, total protein ubiquitination, and tripartite motif-containing protein 32 levels were significantly lower than healthy controls, whereas at 24 h RNO treatment, myotube myosin heavy chain ( MyHC) -I and MyHC-IIx expression levels were upregulated in both patients and controls. In the 6-h RNO cohort, in patients and controls, myotube expression of nuclear factor (erythroid-derived 2)-like 2 ( NRF2) and its downstream antioxidants sirtuin-1, FGF-inducible 14, and insulin-like growth factor-1 was upregulated, whereas that of myocyte-specific enhancer factor 2C, myogenic differentiation, myogenin, myostatin, atrogin-1, and muscle RING-finger protein-1 was downregulated. In myotubes of severe COPD patients with cachexia, roflumilast-induced cAMP signaling exerts beneficial effects by targeting muscle protein breakdown (tyrosine release), along with reduced expression of proteolytic markers of the ubiquitin-proteasome system and that of myostatin. In both patients and controls, roflumilast also favored antioxidant defense through upregulation of the NRF2 pathway and that of the histone deacetylase sirtuin-1, whereas it improved the expression of slow- and fast-twitch myosin isoforms. These findings show that muscle dysfunction and wasting may be targeted by roflumilast-induced cAMP signaling in COPD. These results have potential therapeutic implications, as this PDE-4 inhibitor is currently available for the treatment of systemic inflammation and exacerbations in patients with severe COPD. NEW & NOTEWORTHY In myotubes of cachectic chronic obstructive pulmonary disease (COPD) patients, cAMP signaling exerted beneficial effects by targeting muscle proteolysis and reducing gene expression of proteolytic markers of the ubiquitin-proteasome system and that of myostatin. In myotubes of patients and controls, roflumilast also favored antioxidant defense through upregulation of the nuclear factor (erythroid-derived 2)-like 2 pathway, of sirtuin-1, and of gene expression of slow- and fast-twitch isoforms. These findings have potential clinical implications for the treatment of muscle wasting in patients with COPD and cachexia., Support for this study was provided by CIBERES, FIS 14/00713 (FEDER), SAF-2014-54371-R, SEPAR 2016, FUCAP 2016 (Spain), and an unrestricted grant from Takeda (Japan). E. Barreiro was a recipient of the ERS COPD Research Award 2008.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Differences in micro-RNA expression profile between vastus lateralis samples and myotubes in COPD cachexia

  • Barreiro Portela, Esther
  • Sancho Muñoz, Antonio
  • Puig Vilanova, Ester, 1987-
  • Salazar Degracia, Anna
  • Pascual Guàrdia, Sergi, 1979-
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
Quadriceps muscle weakness and wasting are common comorbidities in chronic obstructive pulmonary disease (COPD). Micro-RNA expression upregulation may favor muscle mass growth and differentiation. We hypothesized that the profile of muscle-enriched micro-RNAs in cultured myotubes differs between patients with COPD of a wide range of body composition and healthy controls and that expression levels of those micro-RNAs from patients with COPD and controls differ between in vivo and in vitro conditions. Twenty-nine patients with COPD [ n = 15 with muscle wasting and fat-free mass index (FFMI) 15 kg/m2 and n = 14 with normal body composition and FFMI 18 kg/m2] and 10 healthy controls (FFMI 19 kg/m2) were consecutively recruited. Biopsies from the vastus lateralis muscle were obtained in all study subjects. A fragment of each biopsy was used to obtain primary cultures, in which muscle cells were first proliferated to be then differentiated into actual myotubes. In both sets of experiments (in vivo biopsies and in vitro myotubes) the following muscle-enriched micro-RNAs from all the study subjects were analyzed using quantitative real-time PCR amplification: micro-RNA (miR)-1, miR-133a, miR-206, miR-486, miR-29b, miR-27a, and miR-181a. Whereas the expression of miR-1, miR-206, miR-486, and miR-29b was upregulated in the muscle biopsies of patients with COPD compared with those of healthy controls, levels of none of the studied micro-RNAs in the myotubes (primary cultured cells) significantly differed between patients with COPD and the controls. We conclude from these findings that environmental factors (blood flow, muscle metabolism, and inflammation) taking place in vivo (biopsies) in muscles may account for the differences observed in micro-RNA expression between patients with COPD and controls. In the myotubes, however, the expression of the same micro-RNAs did not differ between the study subjects as such environmental factors were not present. These findings suggest that therapeutic strategies should rather target environmental factors in COPD muscle wasting as the profile of micro-RNA expression in myotubes was similar in patients to that observed in the healthy controls. NEW & NOTEWORTHY Environmental factors taking place in vivo (biopsies) in the muscles may explain differences observed in micro-RNA expression between patients with chronic obstructive pulmonary disease (COPD) and controls. In the myotubes, however, the expression of the same micro-RNAs did not differ between the study subjects as such environmental factors were not present. These findings suggest that therapeutic strategies should rather target environmental factors in COPD muscle wasting and cachexia as micro-RNA expression profile in myotubes was similar between patients and controls., This study was supported by Centro de Investigación en Red de Enfermedades Respiratorias, Fondo de Investigación Sanitaria (FIS) 14/00713 [Fondo Europeo de Desarrollo Regional (FEDER)], FIS 18/00075 (FEDER), Grant SAF2014-54371, Sociedad Española de Neumología y Cirugía Torácica (SEPAR) 2016, SEPAR 2018, Fundació Catalana de Pneumologia 2016, and an unrestricted grant from Menarini SA 2018 (Spain). E. Barreiro was a recipient of the European Respiratory Society COPD Research Award 2008.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Inspiratory muscle activation increases with COPD severity as confirmed by non-invasive mechanomyographic analysis

  • Sarlabous, Leonardo
  • Torres, Abel
  • Fiz, José Antonio
  • Martínez-Llorens, Juana Mª
  • Gea Guiral, Joaquim
  • Jané, Raimon
There is a lack of instruments for assessing respiratory muscle activation during the breathing cycle in clinical conditions. The aim of the present study was to evaluate the usefulness of the respiratory muscle mechanomyogram (MMG) for non-invasively assessing the mechanical activation of the inspiratory muscles of the lower chest wall in both patients with chronic obstructive pulmonary disease (COPD) and healthy subjects, and to investigate the relationship between inspiratory muscle activation and pulmonary function parameters. Both inspiratory mouth pressure and respiratory muscle MMG were simultaneously recorded under two different respiratory conditions, quiet breathing and incremental ventilatory effort, in 13 COPD patients and 7 healthy subjects. The mechanical activation of the inspiratory muscles was characterised by the non-linear multistate Lempel-Ziv index (MLZ) calculated over the inspiratory time of the MMG signal. Subsequently, the efficiency of the inspiratory muscle mechanical activation was expressed as the ratio between the peak inspiratory mouth pressure to the amplitude of the mechanical activation. This activation estimated using the MLZ index correlated strongly with peak inspiratory mouth pressure throughout the respiratory protocol in both COPD patients (r = 0.80, p<0.001) and healthy (r = 0.82, p<0.001). Moreover, the greater the COPD severity in patients, the greater the level of muscle activation (r = -0.68, p = 0.001, between muscle activation at incremental ventilator effort and FEV1). Furthermore, the efficiency of the mechanical activation of inspiratory muscle was lower in COPD patients than healthy subjects (7.61±2.06 vs 20.42±10.81, respectively, p = 0.0002), and decreased with increasing COPD severity (r = 0.78, p<0.001, between efficiency of the mechanical activation at incremental ventilatory effort and FEV1). These results suggest that the respiratory muscle mechanomyogram is a good reflection of inspiratory effort and can be used to estimate the efficiency of the mechanical activation of the inspiratory muscles. Both, inspiratory muscle activation and inspiratory muscle mechanical activation efficiency are strongly correlated with the pulmonary function. Therefore, the use of the respiratory muscle mechanomyogram can improve the assessment of inspiratory muscle activation in clinical conditions, contributing to a better understanding of breathing in COPD patients., This work was supported in part by the Secretariat of Universities and Research of the Ministry of Economy and Knowledge of the Generalitat de Catalunya (consolidated research groups GRC 2014 SGR 1569 and 424, and CERCA Programme), the Plan Nacional (SAF2014-54371), and by the Ministry of Economy and Competitiveness of the Spanish Government and the European Regional Development Fund, DPI2015-68820-R (MINECO/FEDER).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Metabolomic signatures predict seven-year mortality in clinically stable COPD patients

  • Enríquez Rodríguez, César Jessé
  • Agranovich, Bella
  • Pascual Guàrdia, Sergi, 1979-
  • Faner, Rosa
  • Camps-Ubach, Ramon
  • Castro-Acosta, Ady Angélica
  • Lopez-Campos, Jose Luis
  • Peces-Barba Romero, Germán
  • Seijó Maceiras, Luis
  • Caguana Vélez, Oswaldo Antonio
  • Rodríguez Chiaradia, Diego Agustín
  • Barreiro Portela, Esther
  • Monsó Molas, Eduard
  • Cosío, Borja G.
  • Abramovich, Ifat
  • Agustí, Alvar
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with high mortality. Early identification of patients at increased risk of death remains a major clinical challenge. This pilot study aimed to explore whether plasma metabolomic profiling could aid in the prediction of long-term (7-year) mortality and provide insight into potential underlying mechanisms. Plasma samples from 54 randomly selected stable COPD patients were analyzed using both untargeted and semi-targeted LC-MS approaches. After excluding patients with unclear death data, non-COPD-related deaths and metabolomic outliers, 41 individuals were included in the final analysis. During follow-up, 13 patients (32%) died, and 28 survived. Univariate analysis identified 12 metabolites—mainly amino acids—that differed significantly between the two groups. Functional analysis suggested a significant disruption in energy production pathways. Predictive models developed using machine learning algorithms, consisting of either ten metabolites alone or nine metabolites plus FEV1, achieved high accuracy for 7-year mortality prediction, with the latter model performing slightly better. Internal validation was conducted using five-fold cross-validation. While exploratory, these findings support the hypothesis that early metabolic alterations, particularly in energy pathways, may contribute to long-term mortality risk in stable COPD patients, and could complement traditional prognostic markers such as FEV1., This study was supported by joint funding from the Spanish Ministry of Economy and Competitiveness and the European Union (project SAF2014-54371); the Instituto de Salud Carlos III (ISCIII) and the European Union (projects PI21/00785 and M-BAE BA22/00009); SEPAR Grants (2016, and 2019); a SOCAP Grant (2020); and an unrestricted grant from Menarini Spain (2015–2019). César Jessé Enríquez-Rodríguez holds a predoctoral fellowship (PFIS, ref. FI22/00003) and a Research Personnel Mobility Grant (M-AES MV23/00012), both awarded by ISCIII and co-funded by the European Union.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
Chronic obstructive pulmonary disease (COPD) will be a major leading cause of death worldwide in the near future. Weakness and atrophy of the quadriceps are associated with a significantly poorer prognosis and increased mortality in COPD. Despite that skeletal muscle dysfunction may affect both respiratory and limb muscle groups in COPD, the latter are frequently more severely affected. Therefore, muscle dysfunction in COPD is a common systemic manifestation that should be evaluated on routine basis in clinical settings. In the present review, several aspects of COPD muscle dysfunction are being reviewed, with special emphasis on the underlying biological mechanisms. Figures on the prevalence of COPD muscle dysfunction and the most relevant etiologic contributors are also provided. Despite that ongoing research will shed light into the contribution of additional mechanisms to COPD muscle dysfunction, current knowledge points toward the involvement of a wide spectrum of cellular and molecular events that are differentially expressed in respiratory and limb muscles. Such mechanisms are thoroughly described in the article. The contribution of epigenetic events on COPD muscle dysfunction is also reviewed. We conclude that in view of the latest discoveries, from now, on new avenues of research should be designed to specifically target cellular mechanisms and pathways that impair muscle mass and function in COPD using pharmacological strategies and/or exercise training modalities., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: CIBERES, FIS 11/02029 (FEDER), FIS 14/ 00713 (FEDER), SAF-2011-26908, SAF-2014-54371-R, SEPAR 2010, SEPAR 2014, FUCAP 2009, FUCAP 2011, FUCAP 2012, and Marato´ TV3 (MTV3-07-1010) (Spain) have contributed to support part of the research described in this review.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Is iron deficiency modulating physical activity in COPD?

  • Martín-Ontiyuelo, Clara
  • Rodó-Pin, Anna
  • Sancho Muñoz, Antonio
  • Martinez-Llorens, Juana María
  • Admetlló Papiol, Mireia
  • Molina Ferragut, Luis
  • Gea Guiral, Joaquim
  • Barreiro Portela, Esther
  • Rodríguez Chiaradia, Diego Agustín
There is evidence that iron plays a key role in the adequate functioning of skeletal muscle. While it has been demonstrated that nonanemic iron deficiency (NAID) affects exercise tolerance and response to exercise training in patients with COPD, the impact on daily physical activities (DPAs) remains unknown. Eighteen COPD patients with NAID (ferritin <100 ng/mL or ferritin 100-299 ng/mL with a transferrin saturation <20%) and 18 COPD patients without this abnormality, matched for age, gender, and the degree of airflow limitation (control group), were enrolled to the study. The primary outcome was the level of DPA assessed by accelerometers. Patients were (mean [SD]) 66 (7) years and were mostly male (70%) and former smokers (52%). Their forced expiratory volume at 1 second was 41 (16)% predicted, carbon monoxide diffusing capacity was 47 (14)% predicted and oxygen arterial pressure reached 70 (11) mmHg. DPA and the number of steps per day were lower in NAID COPD patients compared with controls (physical activity level 1.39 vs 1.59, P<0.05; and 4,402 vs 6,975 steps/day, P<0.05, respectively). The percentage of patients with increased time spent sitting per day (>6 hours) was higher in patients with NAID compared with controls (73% vs 37%, P<0.05). In addition, the percentage of patients doing moderate to vigorous physical activity per day (>3 metabolic equivalents of task, at least 30 minutes) was lower in this group (66% vs 100%, P<0.05). The presence of iron deficiency was associated with reduced DPA in COPD patients. Further studies are needed to evaluate iron reposition and their impact on the level of physical activity in these patients., The authors would like to thank Ana Balañá, Concepción Ballano, and Laura Gutiérrez for their assistance in collecting the data for this study. They want to acknowledge the support of the Instituto de Salud Carlos-III (FIS 14/00713 [FEDER], FIS 18/00075 [FEDER], FIS 17/00649 [FEDER], and BA 17/00025), CIBERES (ESF02/2017), Spanish Respiratory Society (SEPAR) 2016 and 2017 (409/2017), Catalan Foundation of Pulmonology (FUCAP) 2016 and 2017, Catalan Respiratory Society (SOCAP) 2017, Ministerio de Economía y Competitividad (SAF2014-54371 [FEDER]), Menarini (2015–2018), and Vifor Pharma (2017–2018).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients

  • Millares, Laura
  • Pascual Guàrdia, Sergi, 1979-
  • Montón, Concepción
  • García-Nuñez, Marian
  • Lalmolda, Cristina
  • Faner, Rosa
  • Casadevall Fusté, Carme
  • Setó, Laia
  • Capilla, Silvia
  • Moreno, Amàlia
  • Castro-Acosta, Ady Angélica
  • Alvarez-Martinez, Carlos José
  • Sibila, Oriol
  • Peces-Barba Romero, Germán
  • Cosio, Borja G.
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • Monsó Molas, Eduard
Background: The respiratory microbiome is altered in COPD patients but its relationship with core components of the disease, such as the severity of airflow limitation, the frequency of exacerbations or the circulating levels of eosinophils, is unclear. Methods: Cross-sectional study comprising 72 clinically stable COPD patients (mean age 68 [SD 7.9] years; FEV1 48.7 [SD 20.1]% of reference) who provided spontaneous sputum samples for 16S rRNA gene amplification and sequencing. The microbiome composition was analysed with QIIME. Results: We observed that: (1) more severe airflow limitation was associated with reduced relative abundance (RA) of Treponema and an increase in Pseudomonas; (2) patients with ≥2 exacerbations the previous year showed a significantly different bacterial community with respect to non-exacerbators (p = 0.014), with changes in 13 genera, including an increase of Pseudomonas, and finally, (3) peripheral eosinophils levels ≥2% were associated with more diverse microbiome [Chao1 224.51 (74.88) vs 277.39 (78.92) p = 0.006; Shannon 3.94 (1.05) vs 4.54 (1.06) p = 0.020], and a significant increase in the RAs of 20 genera. Conclusion: The respiratory microbiome in clinically stable COPD patients varies significantly according to the severity of airflow limitation, previous history of exacerbations and circulating eosinophils levels., This study was funded by FIS PI15/00167 and PI15/02042 from Instituto de Salud Carlos III (ISCIII), SAF 2014–54371 (FEDER) from Ministerio de Economía y Competitividad, Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Laboratorios Menarini S. A, Fundació Pla Armengol and Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). CIBERES is an initiative of the ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Metabolomic signatures predict seven-year mortality in clinically stable COPD patients

  • Enríquez Rodríguez, César Jessé
  • Agranovich, Bella
  • Pascual Guàrdia, Sergi, 1979-
  • Faner, Rosa
  • Camps-Ubach, Ramon
  • Castro-Acosta, Ady Angélica
  • Lopez-Campos, Jose Luis
  • Peces-Barba Romero, Germán
  • Seijó Maceiras, Luis
  • Caguana Vélez, Oswaldo Antonio
  • Rodríguez Chiaradia, Diego Agustín
  • Barreiro Portela, Esther
  • Monsó Molas, Eduard
  • Cosío, Borja G.
  • Abramovich, Ifat
  • Agustí García-Navarro, Àlvar
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
  • Biomepoc Group
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with high mortality. Early identification of patients at increased risk of death remains a major clinical challenge. This pilot study aimed to explore whether plasma metabolomic profiling could aid in the prediction of long-term (7-year) mortality and provide insight into potential underlying mechanisms. Plasma samples from 54 randomly selected stable COPD patients were analyzed using both untargeted and semi-targeted LC-MS approaches. After excluding patients with unclear death data, non-COPD-related deaths and metabolomic outliers, 41 individuals were included in the final analysis. During follow-up, 13 patients (32%) died, and 28 survived. Univariate analysis identified 12 metabolites 'mainly amino acids' that differed significantly between the two groups. Functional analysis suggested a significant disruption in energy production pathways. Predictive models developed using machine learning algorithms, consisting of either ten metabolites alone or nine metabolites plus FEV, achieved high accuracy for 7-year mortality prediction, with the latter model performing slightly better. Internal validation was conducted using five-fold cross-validation. While exploratory, these findings support the hypothesis that early metabolic alterations, particularly in energy pathways, may contribute to long-term mortality risk in stable COPD patients, and could complement traditional prognostic markers such as FEV., This study was supported by joint funding from the Spanish Ministry of Economy and Competitiveness and the European Union (project SAF2014-54371); the Instituto de Salud Carlos III (ISCIII) and the European Union (projects PI21/00785 and M-BAE BA22/00009); SEPAR Grants (2016, and 2019); a SOCAP Grant (2020); and an unrestricted grant from Menarini Spain (2015-2019). César Jessé Enríquez-Rodríguez holds a predoctoral fellowship (PFIS, ref. FI22/00003) and a Research Personnel Mobility Grant (M-AES MV23/00012), both awarded by ISCIII and co-funded by the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia

  • Barreiro Portela, Esther
  • Puig Vilanova, Ester, 1987-
  • Salazar Degracia, Anna
  • Pascual Guàrdia, Sergi, 1979-
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
Peripheral muscle weakness and mass loss are characteristic features in severe chronic obstructive pulmonary disease (COPD). We hypothesized that the phosphodiesterase (PDE)-4 inhibitor roflumilast-induced cAMP may ameliorate proteolysis and metabolism in skeletal muscles of COPD patients with severe muscle wasting. In myogenic precursor cells (isolated from muscle biopsies and cultured up to obtain differentiated myotubes) from 10 severe COPD patients and 10 healthy controls, which were treated with 1 μM roflumilast N-oxide (RNO) for three time cohorts (1, 6, and 24 h), genes of antioxidant defense and oxidative stress marker, myogenesis and muscle metabolism, proteolysis (tyrosine release assay) and ubiquitin-proteasome system markers, autophagy, and myosin isoforms were analyzed using RT-PCR and immunoblotting. In COPD patients at 6 h RNO treatment, myotube tyrosine release, total protein ubiquitination, and tripartite motif-containing protein 32 levels were significantly lower than healthy controls, whereas at 24 h RNO treatment, myotube myosin heavy chain ( MyHC) -I and MyHC-IIx expression levels were upregulated in both patients and controls. In the 6-h RNO cohort, in patients and controls, myotube expression of nuclear factor (erythroid-derived 2)-like 2 ( NRF2) and its downstream antioxidants sirtuin-1, FGF-inducible 14, and insulin-like growth factor-1 was upregulated, whereas that of myocyte-specific enhancer factor 2C, myogenic differentiation, myogenin, myostatin, atrogin-1, and muscle RING-finger protein-1 was downregulated. In myotubes of severe COPD patients with cachexia, roflumilast-induced cAMP signaling exerts beneficial effects by targeting muscle protein breakdown (tyrosine release), along with reduced expression of proteolytic markers of the ubiquitin-proteasome system and that of myostatin. In both patients and controls, roflumilast also favored antioxidant defense through upregulation of the NRF2 pathway and that of the histone deacetylase sirtuin-1, whereas it improved the expression of slow- and fast-twitch myosin isoforms. These findings show that muscle dysfunction and wasting may be targeted by roflumilast-induced cAMP signaling in COPD. These results have potential therapeutic implications, as this PDE-4 inhibitor is currently available for the treatment of systemic inflammation and exacerbations in patients with severe COPD. NEW & NOTEWORTHY In myotubes of cachectic chronic obstructive pulmonary disease (COPD) patients, cAMP signaling exerted beneficial effects by targeting muscle proteolysis and reducing gene expression of proteolytic markers of the ubiquitin-proteasome system and that of myostatin. In myotubes of patients and controls, roflumilast also favored antioxidant defense through upregulation of the nuclear factor (erythroid-derived 2)-like 2 pathway, of sirtuin-1, and of gene expression of slow- and fast-twitch isoforms. These findings have potential clinical implications for the treatment of muscle wasting in patients with COPD and cachexia., Support for this study was provided by CIBERES, FIS 14/00713 (FEDER), SAF-2014-54371-R, SEPAR 2016, FUCAP 2016 (Spain), and an unrestricted grant from Takeda (Japan). E. Barreiro was a recipient of the ERS COPD Research Award 2008.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inspiratory muscle activation increases with COPD severity as confirmed by non-invasive mechanomyographic analysis

  • Sarlabous, Leonardo
  • Torres, Abel
  • Fiz, José Antonio
  • Martínez-Llorens, Juana Mª
  • Gea Guiral, Joaquim
  • Jané, Raimon
There is a lack of instruments for assessing respiratory muscle activation during the breathing cycle in clinical conditions. The aim of the present study was to evaluate the usefulness of the respiratory muscle mechanomyogram (MMG) for non-invasively assessing the mechanical activation of the inspiratory muscles of the lower chest wall in both patients with chronic obstructive pulmonary disease (COPD) and healthy subjects, and to investigate the relationship between inspiratory muscle activation and pulmonary function parameters. Both inspiratory mouth pressure and respiratory muscle MMG were simultaneously recorded under two different respiratory conditions, quiet breathing and incremental ventilatory effort, in 13 COPD patients and 7 healthy subjects. The mechanical activation of the inspiratory muscles was characterised by the non-linear multistate Lempel-Ziv index (MLZ) calculated over the inspiratory time of the MMG signal. Subsequently, the efficiency of the inspiratory muscle mechanical activation was expressed as the ratio between the peak inspiratory mouth pressure to the amplitude of the mechanical activation. This activation estimated using the MLZ index correlated strongly with peak inspiratory mouth pressure throughout the respiratory protocol in both COPD patients (r = 0.80, p<0.001) and healthy (r = 0.82, p<0.001). Moreover, the greater the COPD severity in patients, the greater the level of muscle activation (r = -0.68, p = 0.001, between muscle activation at incremental ventilator effort and FEV1). Furthermore, the efficiency of the mechanical activation of inspiratory muscle was lower in COPD patients than healthy subjects (7.61±2.06 vs 20.42±10.81, respectively, p = 0.0002), and decreased with increasing COPD severity (r = 0.78, p<0.001, between efficiency of the mechanical activation at incremental ventilatory effort and FEV1). These results suggest that the respiratory muscle mechanomyogram is a good reflection of inspiratory effort and can be used to estimate the efficiency of the mechanical activation of the inspiratory muscles. Both, inspiratory muscle activation and inspiratory muscle mechanical activation efficiency are strongly correlated with the pulmonary function. Therefore, the use of the respiratory muscle mechanomyogram can improve the assessment of inspiratory muscle activation in clinical conditions, contributing to a better understanding of breathing in COPD patients., This work was supported in part by the Secretariat of Universities and Research of the Ministry of Economy and Knowledge of the Generalitat de Catalunya (consolidated research groups GRC 2014 SGR 1569 and 424, and CERCA Programme), the Plan Nacional (SAF2014-54371), and by the Ministry of Economy and Competitiveness of the Spanish Government and the European Regional Development Fund, DPI2015-68820-R (MINECO/FEDER).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
Chronic obstructive pulmonary disease (COPD) will be a major leading cause of death worldwide in the near future. Weakness and atrophy of the quadriceps are associated with a significantly poorer prognosis and increased mortality in COPD. Despite that skeletal muscle dysfunction may affect both respiratory and limb muscle groups in COPD, the latter are frequently more severely affected. Therefore, muscle dysfunction in COPD is a common systemic manifestation that should be evaluated on routine basis in clinical settings. In the present review, several aspects of COPD muscle dysfunction are being reviewed, with special emphasis on the underlying biological mechanisms. Figures on the prevalence of COPD muscle dysfunction and the most relevant etiologic contributors are also provided. Despite that ongoing research will shed light into the contribution of additional mechanisms to COPD muscle dysfunction, current knowledge points toward the involvement of a wide spectrum of cellular and molecular events that are differentially expressed in respiratory and limb muscles. Such mechanisms are thoroughly described in the article. The contribution of epigenetic events on COPD muscle dysfunction is also reviewed. We conclude that in view of the latest discoveries, from now, on new avenues of research should be designed to specifically target cellular mechanisms and pathways that impair muscle mass and function in COPD using pharmacological strategies and/or exercise training modalities., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: CIBERES, FIS 11/02029 (FEDER), FIS 14/ 00713 (FEDER), SAF-2011-26908, SAF-2014-54371-R, SEPAR 2010, SEPAR 2014, FUCAP 2009, FUCAP 2011, FUCAP 2012, and Marato´ TV3 (MTV3-07-1010) (Spain) have contributed to support part of the research described in this review.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

  • Enríquez Rodríguez, César Jessé
  • Casadevall Fusté, Carme
  • Faner, Rosa
  • Castro Costa, Ady
  • Pascual Guàrdia, Sergi, 1979-
  • Seijó Maceiras, Luis
  • López Campos, José Luis
  • Peces-Barba Romero, Germán
  • Monsó Molas, Eduard
  • Barreiro Portela, Esther
  • Cosío, Borja G.
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • BIOMEPOC group
Data de publicació electrònica: 25-03-2024, Background: Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE). The objective of the present study was to contrast the systemic proteomic profile in FE versus NFE. As a reference, we also determined the systemic proteomic profile of healthy controls (HC) and COPD patients during an actual episode of exacerbation (AE). Methods: In the analysis we included 40 clinically stable COPD patients (20 FE and 20 NFE), and 20 HC and 10 AE patients. Their plasma samples were analysed by combining two complementary proteomic approaches: label-free liquid chromatography-tandem mass spectrometry and multiplex immunoassays. Gene Ontology annotation, pathway enrichment and network analyses were used to investigate molecular pathways associated with differentially abundant proteins/peptides (DAPs). Results: Compared with HC, we identified 40 DAPs in FE, 10 in NFE and 63 in AE. Also compared to HC, pathway functional and protein-protein network analyses revealed dysregulation of inflammatory responses involving innate and antibody-mediated immunity in COPD, particularly in the FE group, as well as during an AE episode. Besides, we only identified alterations in the complement and coagulation cascades in AE. Conclusion: There are specific plasma proteome profiles associated with FE, which are partially shared with findings observed during AE, albeit others are uniquely present during the actual episode of AE., Support statement: Funded by project SAF2014-54371 from the Spanish Ministerio de Economía y Competitividad and co-funded by the European Union, project PI21/00785 from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, SEPAR 2015, 2016 and 2019, FUCAP 2014, SOCAP 2020, and Menarini (unrestricted Grant 2015-19). C.J. Enríquez-Rodríguez is a recipient of a Predoctoral Grant PFIS from ISCIII and co-funded by the European Union (ref. FI22/00003). Funding information for this article has been deposited with the Crossref Funder Registry.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Relationship between respiratory microbiome and systemic inflammatory markers in COPD: A pilot study

  • Casadevall Fusté, Carme
  • Quero, Sara
  • Millares, Laura
  • Faner, Rosa
  • Cosío, Borja G.
  • Peces-Barba Romero, Germán
  • Castro-Acosta, Ady Angélica
  • Montón, Concepción
  • Palou, Alexandre
  • Pascual Guàrdia, Sergi, 1979-
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • Monsó Molas, Eduard
  • BIOMEPOC group
The respiratory microbiome may influence the development and progression of COPD by modulating local immune and inflammatory events. We aimed to investigate whether relative changes in respiratory bacterial abundance are also associated with systemic inflammation, and explore their relationship with the main clinical COPD phenotypes. Multiplex analysis of inflammatory markers and transcript eosinophil-related markers were analyzed on peripheral blood in a cohort of stable COPD patients (n = 72). Respiratory microbiome composition was analyzed by 16S rRNA microbial sequencing on spontaneous sputum. Spearman correlations were applied to test the relationship between the microbiome composition and systemic inflammation. The concentration of the plasma IL-8 showed an inverted correlation with the relative abundance of 17 bacterial genera in the whole COPD cohort. COPD patients categorized as eosinophilic showed positive relationships with blood eosinophil markers and inversely correlated with the degree of airway obstruction and the number of exacerbations during the previous year. COPD patients categorized as frequent exacerbators were enriched with the bacterial genera Pseudomonas which, in turn, was positively associated with the severity of airflow limitation and the prior year's exacerbation history. The associative relationships of the sputum microbiome with the severity of the disease emphasize the relevance of the interaction between the respiratory microbiota and systemic inflammation., This research was funded by Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), ref. CB06/06/0043 and CB06/06/1097; Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, co-funded by the European Union, grant number PI18/00934 and PI21/00785; Spanish Ministry of Economy and Competitivity, co-funded by the European Union, grant number SAF2014-54371; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) ref: 2017SGR442 and 2021SGR-00100; Sociedad Española de Neumología y Cirugía Torácica (SEPAR), grant number 2015 and 2019; Societat Catalana de Pneumologia (SOCAP) grant number 2020 Research Grant. The funders had no role in the design, data collection, data analysis, and reporting of this study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hospital admissions and mortality in patients with COPD exacerbations and vertebral body compression fractures

  • Pascual Guàrdia, Sergi, 1979-
  • Badenes Bonet, Diana, 1987-
  • Martín-Ontiyuelo, Clara
  • Zuccarino, Flavio
  • Marín Corral, Judith
  • Rodríguez, Alejandro
  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
BACKGROUND: Vertebral compression fractures (VCF) are common in COPD patients, with osteoporosis being the main cause. The clinical impact of VCF derives mostly from both pain and chest deformity, which may lead to ventilatory and physical activity limitations. Surprisingly, the consequences of VCF on the quality outcomes of hospital care are poorly known. OBJECTIVE: To assess these indicators in patients hospitalized due to a COPD exacerbation (ECOPD) who also have VCF. METHODS: Clinical characteristics and quality care indicators were assessed in two one-year periods, one retrospective (exploratory) and one prospective (validation), in all consecutive patients hospitalized for ECOPD. Diagnosis of VCF was based on the reduction of >20% height of the vertebral body evaluated in standard lateral chest X-ray (three independent observers). RESULTS: From the 248 patients admitted during the exploratory phase, a third had at least one VCF. Underdiagnosis rate was 97.6%, and patients with VCF had more admissions (normalized for survival), longer hospital stays, and higher mortality than patients without (4 [25th-75th percentiles, 2-8] vs 3 [1-6] admissions, P<0.01; 12 [6-30] vs 9 [6-18] days, P<0.05; and 50 vs 32.1% deaths, P<0.01, respectively). The risk of dying in the two following years was also higher in VCF patients (odds ratio: 2.11 [1.2-3.6], P<0.01). The validation cohort consisted of 250 patients who showed very similar results. The logistic regression analysis indicated that both VCF and age were factors independently associated with mortality. CONCLUSION: Although VCF is frequently underdiagnosed in patients hospitalized for ECOPD, it is strongly associated with a worse prognosis and quality care outcomes., This study has been partially funded by SEPAR (264/2012), CIBERES, FIS (12/02534), Plan Nacional I+D+i (SAF-2014 – 54371), Generalitat de Catalunya (2009-SGR-393), and FUCAP (2012).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Bispectral index in hypercapnic encephalopathy associated with COPD exacerbation: a pilot study

  • Chalela Rengifo, Roberto José, 1985-
  • Gallart Gallego, Lluís
  • Pascual Guàrdia, Sergi, 1979-
  • Sancho Muñoz, Antonio
  • Gea Guiral, Joaquim
  • Orozco Levi, Mauricio
Background: Hypercapnic encephalopathy is relatively frequent in severe exacerbations of COPD (ECOPDs), with its intensity usually being evaluated through clinical scales. Bispectral index (BIS) is a relatively new technique, based on the analysis of the electroencephalographic signal, which provides a good approximation to the level of consciousness, having already been validated in anesthesia. Objective: The objective of the study was to evaluate the utility of BIS in the assessment of the intensity of hypercapnic encephalopathy in ECOPD patients. Patients and methods: A total of ten ECOPD patients were included, and the level of brain activity was assessed using BIS and different scales: Glasgow Coma Scale, Ramsay Sedation Scale (RSS), and Richmond Agitation–Sedation Scale. The evaluation was performed both in the acute phase and 3 months after discharge. Results: BIS was recorded for a total of about 600 minutes. During ECOPD, BIS values ranged from 58.8 (95% CI: 48.6–69) for RSS score of 4 to 92.2 (95% CI: 90.1–94.3) for RSS score of 2. A significant correlation was observed between values obtained with BIS and those from the three scales, although the best fit was for RSS, followed by Glasgow and Richmond (r=-0.757, r=0.701, and r=0.615, respectively; P<0.001 for all). In the stable phase after discharge, BIS showed values considered as normal for a wake state (94.6; 95% CI: 91.7–97.9). Conclusion: BIS may be useful for the objective early detection and automatic monitoring of the intensity of hypercapnic encephalopathy in ECOPD, facilitating the early detection and follow-up of this condition, which may avoid management problems in these patients., We are thankful to Jonathan McFarland for his editing aid and to Mireia Admetllo and Camino Fernández for their help in collecting clinical data. This project was funded in part by SAF SAF2014-54371, CIBERES, BRN-Pla Armengol 2014, 2014SGR424, SEPAR 2015, and SEPAR Becario 2015.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differences in micro-RNA expression profile between vastus lateralis samples and myotubes in COPD cachexia

  • Barreiro Portela, Esther
  • Sancho Muñoz, Antonio
  • Puig Vilanova, Ester, 1987-
  • Salazar Degracia, Anna
  • Pascual Guàrdia, Sergi, 1979-
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
Quadriceps muscle weakness and wasting are common comorbidities in chronic obstructive pulmonary disease (COPD). Micro-RNA expression upregulation may favor muscle mass growth and differentiation. We hypothesized that the profile of muscle-enriched micro-RNAs in cultured myotubes differs between patients with COPD of a wide range of body composition and healthy controls and that expression levels of those micro-RNAs from patients with COPD and controls differ between in vivo and in vitro conditions. Twenty-nine patients with COPD [ n = 15 with muscle wasting and fat-free mass index (FFMI) 15 kg/m2 and n = 14 with normal body composition and FFMI 18 kg/m2] and 10 healthy controls (FFMI 19 kg/m2) were consecutively recruited. Biopsies from the vastus lateralis muscle were obtained in all study subjects. A fragment of each biopsy was used to obtain primary cultures, in which muscle cells were first proliferated to be then differentiated into actual myotubes. In both sets of experiments (in vivo biopsies and in vitro myotubes) the following muscle-enriched micro-RNAs from all the study subjects were analyzed using quantitative real-time PCR amplification: micro-RNA (miR)-1, miR-133a, miR-206, miR-486, miR-29b, miR-27a, and miR-181a. Whereas the expression of miR-1, miR-206, miR-486, and miR-29b was upregulated in the muscle biopsies of patients with COPD compared with those of healthy controls, levels of none of the studied micro-RNAs in the myotubes (primary cultured cells) significantly differed between patients with COPD and the controls. We conclude from these findings that environmental factors (blood flow, muscle metabolism, and inflammation) taking place in vivo (biopsies) in muscles may account for the differences observed in micro-RNA expression between patients with COPD and controls. In the myotubes, however, the expression of the same micro-RNAs did not differ between the study subjects as such environmental factors were not present. These findings suggest that therapeutic strategies should rather target environmental factors in COPD muscle wasting as the profile of micro-RNA expression in myotubes was similar in patients to that observed in the healthy controls. NEW & NOTEWORTHY Environmental factors taking place in vivo (biopsies) in the muscles may explain differences observed in micro-RNA expression between patients with chronic obstructive pulmonary disease (COPD) and controls. In the myotubes, however, the expression of the same micro-RNAs did not differ between the study subjects as such environmental factors were not present. These findings suggest that therapeutic strategies should rather target environmental factors in COPD muscle wasting and cachexia as micro-RNA expression profile in myotubes was similar between patients and controls., This study was supported by Centro de Investigación en Red de Enfermedades Respiratorias, Fondo de Investigación Sanitaria (FIS) 14/00713 [Fondo Europeo de Desarrollo Regional (FEDER)], FIS 18/00075 (FEDER), Grant SAF2014-54371, Sociedad Española de Neumología y Cirugía Torácica (SEPAR) 2016, SEPAR 2018, Fundació Catalana de Pneumologia 2016, and an unrestricted grant from Menarini SA 2018 (Spain). E. Barreiro was a recipient of the European Respiratory Society COPD Research Award 2008.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Metabolomic signatures predict seven-year mortality in clinically stable COPD patients

  • Enríquez Rodríguez, César Jessé
  • Agranovich, Bella
  • Pascual Guàrdia, Sergi, 1979-
  • Faner, Rosa
  • Camps-Ubach, Ramon
  • Castro-Acosta, Ady Angélica
  • Lopez-Campos, Jose Luis
  • Peces-Barba Romero, Germán
  • Seijó Maceiras, Luis
  • Caguana Vélez, Oswaldo Antonio
  • Rodríguez Chiaradia, Diego Agustín
  • Barreiro Portela, Esther
  • Monsó Molas, Eduard
  • Cosío, Borja G.
  • Abramovich, Ifat
  • Agustí, Alvar
  • Casadevall Fusté, Carme
  • Gea Guiral, Joaquim
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition with high mortality. Early identification of patients at increased risk of death remains a major clinical challenge. This pilot study aimed to explore whether plasma metabolomic profiling could aid in the prediction of long-term (7-year) mortality and provide insight into potential underlying mechanisms. Plasma samples from 54 randomly selected stable COPD patients were analyzed using both untargeted and semi-targeted LC-MS approaches. After excluding patients with unclear death data, non-COPD-related deaths and metabolomic outliers, 41 individuals were included in the final analysis. During follow-up, 13 patients (32%) died, and 28 survived. Univariate analysis identified 12 metabolites—mainly amino acids—that differed significantly between the two groups. Functional analysis suggested a significant disruption in energy production pathways. Predictive models developed using machine learning algorithms, consisting of either ten metabolites alone or nine metabolites plus FEV1, achieved high accuracy for 7-year mortality prediction, with the latter model performing slightly better. Internal validation was conducted using five-fold cross-validation. While exploratory, these findings support the hypothesis that early metabolic alterations, particularly in energy pathways, may contribute to long-term mortality risk in stable COPD patients, and could complement traditional prognostic markers such as FEV1., This study was supported by joint funding from the Spanish Ministry of Economy and Competitiveness and the European Union (project SAF2014-54371); the Instituto de Salud Carlos III (ISCIII) and the European Union (projects PI21/00785 and M-BAE BA22/00009); SEPAR Grants (2016, and 2019); a SOCAP Grant (2020); and an unrestricted grant from Menarini Spain (2015–2019). César Jessé Enríquez-Rodríguez holds a predoctoral fellowship (PFIS, ref. FI22/00003) and a Research Personnel Mobility Grant (M-AES MV23/00012), both awarded by ISCIII and co-funded by the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients

  • Pascual Guàrdia, Sergi, 1979-
  • Ataya Fernández, Michelle, 1993-
  • Ramírez Martínez, Isabel
  • Yélamos López, José
  • Chalela Rengifo, Roberto José, 1985-
  • Bellido, Salomé
  • López-Botet, M. (Miguel)
  • Gea Guiral, Joaquim
Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive disorder with a heterogeneous presentation and frequent systemic manifestations. Several aspects like persistence in smoking habit, continuous exacerbations, alpha-1-antitrypsin deficiency and inflammatory-immune response, are involved in the pathophysiology and progression of the disease. However, the role of natural killer (NK) cells remains controversial. Otherwise, human cytomegalovirus (HCMV) infection has been reported to induce an adaptive differentiation and expansion of an NK cell subset which carries the CD94/NKG2C receptor, which may contribute to an upset immune defense. For these reasons, our objective is to assess the distribution of NK cells and their subset in COPD patients and some of its phenotypes. Methods: Peripheral blood samples were obtained from 66 COPD patients. HCMV serology and the proportions of total NK cells and the NKG2C+ and NKG2A+ subsets were evaluated by flow cytometry. The NKG2C genotype was also assessed. Results: Eighty-eight per cent of COPD patients were HCMV(+), and the proportions of total NK cells were higher in patients with severe-very severe airway obstruction than in those with only mild-moderate involvement. There were no differences in the proportions of NKG2C+ cells between controls and COPD, either among COPD patients classified by severity of the disease. However, the percentage of NKG2C+ cells were higher in COPD patients with frequent exacerbations than in occasional exacerbators, and higher in cases with reduced lean mass (Fat free mass index) than in those with normal nutritional status. Conclusion: These results suggest a relationship between levels of NKG2C+ cells in COPD patients and clinical variables closely linked to a poor/worse prognosis., SEPAR 2015, MINECO Plan Estatal I + D Retos (SAF2013–49063-C2–1-R, SAF2016–80363-C2–1-R y SAF2014–54371) (FEDER Funds), FUCAP & Menarini.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Is iron deficiency modulating physical activity in COPD?

  • Martín-Ontiyuelo, Clara
  • Rodó-Pin, Anna
  • Sancho Muñoz, Antonio
  • Martinez-Llorens, Juana María
  • Admetlló Papiol, Mireia
  • Molina Ferragut, Luis
  • Gea Guiral, Joaquim
  • Barreiro Portela, Esther
  • Rodríguez Chiaradia, Diego Agustín
There is evidence that iron plays a key role in the adequate functioning of skeletal muscle. While it has been demonstrated that nonanemic iron deficiency (NAID) affects exercise tolerance and response to exercise training in patients with COPD, the impact on daily physical activities (DPAs) remains unknown. Eighteen COPD patients with NAID (ferritin <100 ng/mL or ferritin 100-299 ng/mL with a transferrin saturation <20%) and 18 COPD patients without this abnormality, matched for age, gender, and the degree of airflow limitation (control group), were enrolled to the study. The primary outcome was the level of DPA assessed by accelerometers. Patients were (mean [SD]) 66 (7) years and were mostly male (70%) and former smokers (52%). Their forced expiratory volume at 1 second was 41 (16)% predicted, carbon monoxide diffusing capacity was 47 (14)% predicted and oxygen arterial pressure reached 70 (11) mmHg. DPA and the number of steps per day were lower in NAID COPD patients compared with controls (physical activity level 1.39 vs 1.59, P<0.05; and 4,402 vs 6,975 steps/day, P<0.05, respectively). The percentage of patients with increased time spent sitting per day (>6 hours) was higher in patients with NAID compared with controls (73% vs 37%, P<0.05). In addition, the percentage of patients doing moderate to vigorous physical activity per day (>3 metabolic equivalents of task, at least 30 minutes) was lower in this group (66% vs 100%, P<0.05). The presence of iron deficiency was associated with reduced DPA in COPD patients. Further studies are needed to evaluate iron reposition and their impact on the level of physical activity in these patients., The authors would like to thank Ana Balañá, Concepción Ballano, and Laura Gutiérrez for their assistance in collecting the data for this study. They want to acknowledge the support of the Instituto de Salud Carlos-III (FIS 14/00713 [FEDER], FIS 18/00075 [FEDER], FIS 17/00649 [FEDER], and BA 17/00025), CIBERES (ESF02/2017), Spanish Respiratory Society (SEPAR) 2016 and 2017 (409/2017), Catalan Foundation of Pulmonology (FUCAP) 2016 and 2017, Catalan Respiratory Society (SOCAP) 2017, Ministerio de Economía y Competitividad (SAF2014-54371 [FEDER]), Menarini (2015–2018), and Vifor Pharma (2017–2018).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A pilot study on proteomic predictors of mortality in stable COPD

  • Enríquez Rodríguez, César Jessé
  • Casadevall Fusté, Carme
  • Faner, Rosa
  • Pascual Guàrdia, Sergi, 1979-
  • Castro-Acosta, Ady Angélica
  • López Campos, José Luis
  • Peces-Barba Romero, Germán
  • Seijo, Luis
  • Caguana Vélez, Oswaldo Antonio
  • Monsó Molas, Eduard
  • Rodríguez Chiaradia, Diego Agustín
  • Barreiro Portela, Esther
  • Cosío, Borja G.
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • BIOMEPOC group
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of global mortality. Despite clinical predictors (age, severity, comorbidities, etc.) being established, proteomics offers comprehensive biological profiling to obtain deeper insights into COPD pathophysiology and survival prognoses. This pilot study aimed to identify proteomic footprints that could be potentially useful in predicting mortality in stable COPD patients. Plasma samples from 40 patients were subjected to both blind (liquid chromatography-mass spectrometry) and hypothesis-driven (multiplex immunoassays) proteomic analyses supported by artificial intelligence (AI) before a 4-year clinical follow-up. Among the 34 patients whose survival status was confirmed (mean age 69 ± 9 years, 29.5% women, FEV1 42 ± 15.3% ref.), 32% were dead in the fourth year. The analysis identified 363 proteins/peptides, with 31 showing significant differences between the survivors and non-survivors. These proteins predominantly belonged to different aspects of the immune response (12 proteins), hemostasis (9), and proinflammatory cytokines (5). The predictive modeling achieved excellent accuracy for mortality (90%) but a weaker performance for days of survival (Q2 0.18), improving mildly with AI-mediated blind selection of proteins (accuracy of 95%, Q2 of 0.52). Further stratification by protein groups highlighted the predictive value for mortality of either hemostasis or pro-inflammatory markers alone (accuracies of 95 and 89%, respectively). Therefore, stable COPD patients' proteomic footprints can effectively forecast 4-year mortality, emphasizing the role of inflammatory, immune, and cardiovascular events. Future applications may enhance the prognostic precision and guide preventive interventions., This research was co-funded by the Spanish Ministerio de Economía y Competitividad and the European Union (project SAF2014-54371); the Instituto de Salud Carlos III (ISCIII) and European Union (projects PI21/00785 and M-BAE BA22/00009); SEPAR Grants (2015, 2016 and 2019); an FUCAP Grant (2014); an SOCAP Grant (2020); and Menarini Spain (unrestricted Grant 2015-19). César J. Enríquez-Rodríguez is a recipient of a Predoctoral Grant PFIS (ref. FI22/00003) and a Mobility of Research Personnel Grant (M-AES MV23/00012) from ISCIII and co-funded by the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PARP-1 and PARP-2 activity in cancer-induced cachexia: potential therapeutic implications

  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
Skeletal muscle dysfunction and mass loss is a characteristic feature in patients with chronic diseases including cancer and acute conditions such as critical illness. Maintenance of an adequate muscle mass is crucial for the patients' prognosis irrespective of the underlying condition. Moreover, aging-related sarcopenia may further aggravate the muscle wasting process associated with chronic diseases and cancer. Poly(adenosine diphosphate-ribose) polymerase (PARP) activation has been demonstrated to contribute to the pathophysiology of muscle mass loss and dysfunction in animal models of cancer-induced cachexia. Genetic inhibition of PARP activity attenuated the deleterious effects seen on depleted muscles in mouse models of oncologic cachexia. In the present minireview the mechanisms whereby PARP activity inhibition may improve muscle mass and performance in models of cancer-induced cachexia are discussed. Specifically, the beneficial effects of inhibition of PARP activity on attenuation of increased oxidative stress, protein catabolism, poor muscle anabolism and mitochondrial content and epigenetic modulation of muscle phenotype are reviewed in this article. Finally, the potential therapeutic strategies of pharmacological PARP activity inhibition for the treatment of cancer-induced cachexia are also being described in this review., CIBERES, FIS 14/00713 (PEDER), SAF-2014-54371-R, SEPAR 2016, and FUCAP 2016 (Spain) have contributed to support part of the research described in this review.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Is iron deficiency modulating physical activity in COPD?

  • Martín-Ontiyuelo, Clara
  • Rodó-Pin, Anna
  • Sancho-Muñoz, Antonio
  • Martinez-Llorens, Juana María
  • Admetlló, Mireia|||0000-0002-4315-5534
  • Molina, Lluis
  • Gea Guiral, Joaquim
  • Barreiro, Esther|||0000-0003-2708-3443
  • Chiaradía, Diego A. Rodríguez
There is evidence that iron plays a key role in the adequate functioning of skeletal muscle. While it has been demonstrated that nonanemic iron deficiency (NAID) affects exercise tolerance and response to exercise training in patients with COPD, the impact on daily physical activities (DPAs) remains unknown. Eighteen COPD patients with NAID (ferritin <100 ng/mL or ferritin 100-299 ng/mL with a transferrin saturation <20%) and 18 COPD patients without this abnormality, matched for age, gender, and the degree of airflow limitation (control group), were enrolled to the study. The primary outcome was the level of DPA assessed by accelerometers. Patients were (mean [SD]) 66 (7) years and were mostly male (70%) and former smokers (52%). Their forced expiratory volume at 1 second was 41 (16)% predicted, carbon monoxide diffusing capacity was 47 (14)% predicted and oxygen arterial pressure reached 70 (11) mmHg. DPA and the number of steps per day were lower in NAID COPD patients compared with controls (physical activity level 1.39 vs 1.59, P <0.05; and 4,402 vs 6,975 steps/day, P <0.05, respectively). The percentage of patients with increased time spent sitting per day (>6 hours) was higher in patients with NAID compared with controls (73% vs 37%, P <0.05). In addition, the percentage of patients doing moderate to vigorous physical activity per day (>3 metabolic equivalents of task, at least 30 minutes) was lower in this group (66% vs 100%, P <0.05). The presence of iron deficiency was associated with reduced DPA in COPD patients. Further studies are needed to evaluate iron reposition and their impact on the level of physical activity in these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients

  • Millares, Laura|||0000-0002-0242-0274
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Montón, Concepción
  • Garcia-Nuñez, Marian|||0000-0002-5158-3758
  • Lalmolda, Cristina|||0000-0002-1128-9028
  • Faner, Rosa|||0000-0002-8159-0115
  • Casadevall, Carme|||0000-0001-6458-8972
  • Setó, Laia
  • Capilla, Silvia|||0000-0002-7274-2973
  • Moreno Gomez de Bonilla, Amalia|||0009-0005-7405-1833
  • Castro Acosta, Ady|||0000-0001-7591-6011
  • Alvarez-Martinez, Carlos José
  • Sibila, Oriol|||0000-0002-4833-6713
  • Peces-Barba, Germán
  • Cosio, Borja G.|||0000-0002-6388-8209
  • Agustí, Àlvar
  • Gea Guiral, Joaquim|||0000-0001-8718-7346
  • Monso, Eduard|||0000-0003-1876-3092
The respiratory microbiome is altered in COPD patients but its relationship with core components of the disease, such as the severity of airflow limitation, the frequency of exacerbations or the circulating levels of eosinophils, is unclear. Cross-sectional study comprising 72 clinically stable COPD patients (mean age 68 [SD 7.9] years; FEV1 48.7 [SD 20.1]% of reference) who provided spontaneous sputum samples for 16S rRNA gene amplification and sequencing. The microbiome composition was analysed with QIIME. We observed that: (1) more severe airflow limitation was associated with reduced relative abundance (RA) of Treponema and an increase in Pseudomonas ; (2) patients with ≥2 exacerbations the previous year showed a significantly different bacterial community with respect to non-exacerbators (p = 0.014), with changes in 13 genera, including an increase of Pseudomonas, and finally, (3) peripheral eosinophils levels ≥2% were associated with more diverse microbiome [Chao1 224.51 (74.88) vs 277.39 (78.92) p = 0.006; Shannon 3.94 (1.05) vs 4.54 (1.06) p = 0.020], and a significant increase in the RAs of 20 genera. The respiratory microbiome in clinically stable COPD patients varies significantly according to the severity of airflow limitation, previous history of exacerbations and circulating eosinophils levels. The online version of this article (10.1186/s12890-019-0867-x) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bispectral index in hypercapnic encephalopathy associated with COPD exacerbation, a pilot study

  • Chalela, Roberto|||0000-0003-4835-3852
  • Gallart, Lluís|||0000-0002-1478-2002
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Sancho-Muñoz, Antonio
  • Gea Guiral, Joaquim
  • Orozco Levi, Mauricio
Hypercapnic encephalopathy is relatively frequent in severe exacerbations of COPD (ECOPDs), with its intensity usually being evaluated through clinical scales. Bispectral index (BIS) is a relatively new technique, based on the analysis of the electroencephalographic signal, which provides a good approximation to the level of consciousness, having already been validated in anesthesia. The objective of the study was to evaluate the utility of BIS in the assessment of the intensity of hypercapnic encephalopathy in ECOPD patients. A total of ten ECOPD patients were included, and the level of brain activity was assessed using BIS and different scales: Glasgow Coma Scale, Ramsay Sedation Scale (RSS), and Richmond Agitation-Sedation Scale. The evaluation was performed both in the acute phase and 3 months after discharge. BIS was recorded for a total of about 600 minutes. During ECOPD, BIS values ranged from 58.8 (95% CI: 48.6-69) for RSS score of 4 to 92.2 (95% CI: 90.1-94.3) for RSS score of 2. A significant correlation was observed between values obtained with BIS and those from the three scales, although the best fit was for RSS, followed by Glasgow and Richmond (r =-0.757, r =0.701, and r =0.615, respectively; P <0.001 for all). In the stable phase after discharge, BIS showed values considered as normal for a wake state (94.6; 95% CI: 91.7-97.9). BIS may be useful for the objective early detection and automatic monitoring of the intensity of hypercapnic encephalopathy in ECOPD, facilitating the early detection and follow-up of this condition, which may avoid management problems in these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

COPD, systemic proteomic profiles in frequent and infrequent exacerbators

  • Enríquez-Rodríguez, César Jessé|||0000-0002-5944-6555
  • Casadevall, Carme|||0000-0001-6458-8972
  • Faner, Rosa|||0000-0002-8159-0115
  • Castro Acosta, Ady|||0000-0001-7591-6011
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Seijó, Luis|||0000-0001-9344-728X
  • López Campos, José Luis|||0000-0003-1703-1367
  • Peces-Barba, Germán
  • Monso, Eduard|||0000-0003-1876-3092
  • Barreiro, Esther|||0000-0003-2708-3443
  • Cosio, Borja G.|||0000-0002-6388-8209
  • Agustí García-Navarro, Àlvar|||0000-0003-3271-3788
  • Gea Guiral, Joaquim|||0000-0001-8718-7346
Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE). The objective of the present study was to contrast the systemic proteomic profile in FE versus NFE. As a reference, we also determined the systemic proteomic profile of healthy controls (HC) and COPD patients during an actual episode of exacerbation (AE). In the analysis we included 40 clinically stable COPD patients (20 FE and 20 NFE), and 20 HC and 10 AE patients. Their plasma samples were analysed by combining two complementary proteomic approaches: label-free liquid chromatography-tandem mass spectrometry and multiplex immunoassays. Gene Ontology annotation, pathway enrichment and network analyses were used to investigate molecular pathways associated with differentially abundant proteins/peptides (DAPs). Compared with HC, we identified 40 DAPs in FE, 10 in NFE and 63 in AE. Also compared to HC, pathway functional and protein-protein network analyses revealed dysregulation of inflammatory responses involving innate and antibody-mediated immunity in COPD, particularly in the FE group, as well as during an AE episode. Besides, we only identified alterations in the complement and coagulation cascades in AE. There are specific plasma proteome profiles associated with FE, which are partially shared with findings observed during AE, albeit others are uniquely present during the actual episode of AE. Although COPD exacerbations are characterised by a specific plasma proteomic profile, those patients who suffer frequent acute episodes maintain some of these abnormalities, providing a possible biological basis for this phenotype.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship between Respiratory Microbiome and Systemic Inflammatory Markers in COPD, A Pilot Study

  • Casadevall, Carme|||0000-0001-6458-8972
  • Quero, Sara|||0000-0002-6454-6358
  • Millares, Laura|||0000-0002-0242-0274
  • Faner, Rosa|||0000-0002-8159-0115
  • Cosio, Borja G.|||0000-0002-6388-8209
  • Peces-Barba, Germán
  • Castro Acosta, Ady|||0000-0001-7591-6011
  • Montón, Concepción
  • Palou, Alexandre
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Agustí, Àlvar
  • Gea Guiral, Joaquim|||0000-0001-8718-7346
  • Monso, Eduard|||0000-0003-1876-3092
The respiratory microbiome may influence the development and progression of COPD by modulating local immune and inflammatory events. We aimed to investigate whether relative changes in respiratory bacterial abundance are also associated with systemic inflammation, and explore their relationship with the main clinical COPD phenotypes. Multiplex analysis of inflammatory markers and transcript eosinophil-related markers were analyzed on peripheral blood in a cohort of stable COPD patients (n = 72). Respiratory microbiome composition was analyzed by 16S rRNA microbial sequencing on spontaneous sputum. Spearman correlations were applied to test the relationship between the microbiome composition and systemic inflammation. The concentration of the plasma IL-8 showed an inverted correlation with the relative abundance of 17 bacterial genera in the whole COPD cohort. COPD patients categorized as eosinophilic showed positive relationships with blood eosinophil markers and inversely correlated with the degree of airway obstruction and the number of exacerbations during the previous year. COPD patients categorized as frequent exacerbators were enriched with the bacterial genera Pseudomonas which, in turn, was positively associated with the severity of airflow limitation and the prior year's exacerbation history. The associative relationships of the sputum microbiome with the severity of the disease emphasize the relevance of the interaction between the respiratory microbiota and systemic inflammation.